Mark M. Davis
Stanford University
H-index: 167
North America-United States
Description
Mark M. Davis, With an exceptional h-index of 167 and a recent h-index of 99 (since 2020), a distinguished researcher at Stanford University, specializes in the field of immunology.
His recent articles reflect a diverse array of research interests and contributions to the field:
Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus
IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
Lineage tracing defines responding CAR T cells in patients with B cell malignancies
Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study
HLA-DQB1* 05 subtypes and not DRB1* 10: 01 mediates risk in anti-IgLON5 disease
Systems-level immunomonitoring in children with solid tumors
Restrained memory CD8+ T cell responses favors viral persistence and elevated IgG responses in patients with severe Long COVID.
Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques
Professor Information
University | Stanford University |
---|---|
Position | ___ |
Citations(all) | 108842 |
Citations(since 2020) | 33281 |
Cited By | 88961 |
hIndex(all) | 167 |
hIndex(since 2020) | 99 |
i10Index(all) | 490 |
i10Index(since 2020) | 324 |
University Profile Page | Stanford University |
Research & Interests List
immunology
Top articles of Mark M. Davis
Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus
Understanding the immune responses to SARS-CoV-2 vaccination is critical to optimizing vaccination strategies for individuals with autoimmune diseases, such as systemic lupus erythematosus (SLE). Here, we comprehensively analyzed innate and adaptive immune responses in 19 patients with SLE receiving a complete 2-dose Pfizer-BioNTech mRNA vaccine (BNT162b2) regimen compared with a control cohort of 56 healthy control (HC) volunteers. Patients with SLE exhibited impaired neutralizing antibody production and antigen-specific CD4+ and CD8+ T cell responses relative to HC. Interestingly, antibody responses were only altered in patients with SLE treated with immunosuppressive therapies, whereas impairment of antigen-specific CD4+ and CD8+ T cell numbers was independent of medication. Patients with SLE also displayed reduced levels of circulating CXC motif chemokine ligands, CXCL9 …
Authors
Kavita Y Sarin,Hong Zheng,Yashaar Chaichian,Prabhu S Arunachalam,Gayathri Swaminathan,Alec Eschholz,Fei Gao,Oliver F Wirz,Brandon Lam,Emily Yang,Lori W Lee,Allan Feng,Matthew A Lewis,Janice Lin,Holden T Maecker,Scott D Boyd,Mark M Davis,Kari C Nadeau,Bali Pulendran,Purvesh Khatri,Paul J Utz,Lisa C Zaba
Journal
JCI insight
Published Date
2024/3/8
IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
The glycosylation of IgG plays a critical role during human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during human acute viral infection. The analysis of IgM N-glycosylation from healthy controls and hospitalized coronavirus disease 2019 (COVID-19) patients reveals increased high-mannose and sialylation that correlates with COVID-19 severity. These trends are confirmed within SARS-CoV-2-specific immunoglobulin N-glycan profiles. Moreover, the degree of total IgM mannosylation and sialylation correlate significantly with markers of disease severity. We link the changes of IgM N-glycosylation with the expression of Golgi glycosyltransferases. Lastly, we observe antigen-specific IgM antibody-dependent complement deposition is elevated in severe COVID-19 …
Authors
Benjamin S Haslund-Gourley,Kyra Woloszczuk,Jintong Hou,Jennifer Connors,Gina Cusimano,Mathew Bell,Bhavani Taramangalam,Slim Fourati,Nathan Mege,Mariana Bernui,Matthew C Altman,Florian Krammer,Harm van Bakel
Journal
Nature communications
Published Date
2024/1/9
Lineage tracing defines responding CAR T cells in patients with B cell malignancies
Autologous T cells engineered to express a chimeric antigen receptor (CAR) have transformed the standard of care for patients with B cell malignancies, but >50% of patients progress following therapy. Here, we sought to understand key T cell intrinsic factors impacting efficacy: CAR T cell expansion, persistence, and homing to the tumor. Using an endogenous T cell receptor (TCR) sequence as a ‘barcode’, we followed individual T cell clonotypes at the single-cell level from pre-manufacture apheresis and infusion products to tumor-involved lymph nodes and blood at peak and late expansion in 22 adult patients with relapsed or refractory large B cell lymphoma (LBCL) or acute lymphoblastic leukemia (ALL) treated with axicabtagene ciloleucel, an FDA-approved CD19-CAR T cell therapy, or bispecific CD19/CD22-CAR T cells on an investigator-initiated trial (NCT03233854). The resulting CAR T cell atlas …
Authors
Zinaida Good,Mark P Hamilton,Jay Y Spiegel,Moksha H Desai,Zachary J Ehlinger,Patrick J Quinn,Yiyun Chen,Snehit Prabhu,Shin-Heng Chiou,Sreevidya Kurra,Eric Yang,Michael G Ozawa,Matthew J Frank,Lori Muffly,Gursharan K Claire,Sushma Bharadwaj,Saurabh Dahiya,Katherine A Kong,Mark M Davis,Sylvia K Plevritis,Elena Sotillo,Bita Sahaf,David B Miklos,Crystal L Mackall
Journal
Cancer Research
Published Date
2024/3/22
Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study
Post-acute sequelae of SARS-CoV-2 (PASC) is a significant public health concern. We describe Patient Reported Outcomes (PROs) on 590 participants prospectively assessed from hospital admission for COVID-19 through one year after discharge. Modeling identified 4 PRO clusters based on reported deficits (minimal, physical, mental/cognitive, and multidomain), supporting heterogenous clinical presentations in PASC, with sub-phenotypes associated with female sex and distinctive comorbidities. During the acute phase of disease, a higher respiratory SARS-CoV-2 viral burden and lower Receptor Binding Domain and Spike antibody titers were associated with both the physical predominant and the multidomain deficit clusters. A lower frequency of circulating B lymphocytes by mass cytometry (CyTOF) was observed in the multidomain deficit cluster. Circulating fibroblast growth factor 21 (FGF21) was …
Authors
Al Ozonoff,Naresh Doni Jayavelu,Shanshan Liu,Esther Melamed,Carly E Milliren,Jingjing Qi,Linda N Geng,Grace A McComsey,Charles B Cairns,Lindsey R Baden,Joanna Schaenman,Albert C Shaw,Hady Samaha,Vicki Seyfert-Margolis,Florian Krammer,Lindsey B Rosen,Hanno Steen,Caitlin Syphurs,Ravi Dandekar,Casey P Shannon,Rafick P Sekaly,Lauren IR Ehrlich,David B Corry,Farrah Kheradmand,Mark A Atkinson,Scott C Brakenridge,Nelson I Agudelo Higuita,Jordan P Metcalf,Catherine L Hough,William B Messer,Bali Pulendran,Kari C Nadeau,Mark M Davis,Ana Fernandez Sesma,Viviana Simon,Harm van Bakel,Seunghee Kim-Schulze,David A Hafler,Ofer Levy,Monica Kraft,Chris Bime,Elias K Haddad,Carolyn S Calfee,David J Erle,Charles R Langelier,Walter Eckalbar,Steven E Bosinger,IMPACC Network IMPACC Steering Committee
Journal
Nature Communications
Published Date
2024/1/3
HLA-DQB1* 05 subtypes and not DRB1* 10: 01 mediates risk in anti-IgLON5 disease
Anti-IgLON5 disease is a rare and likely underdiagnosed subtype of autoimmune encephalitis. The disease displays a heterogeneous phenotype that includes sleep, movement, and bulbar-associated dysfunction. Presence of IgLON5-antibodies in CSF/serum, together with a strong association with HLA-DRB1*10:01∼DQB1*05:01, support an autoimmune basis. In this study, a multicentric HLA study of 87 anti-IgLON5 patients revealed a stronger association with HLA-DQ than HLA-DR. Specifically, we identified a predisposing rank-wise association with HLA-DQA1*01:05∼DQB1*05:01, HLA-DQA1*01:01∼DQB1*05:01 and HLA-DQA1*01:04∼DQB1*05:03 in 85% of patients. HLA sequences and binding cores for these three DQ heterodimers were similar, unlike those of linked DRB1 alleles, supporting a causal link to HLA-DQ. This association was further reflected in an increasingly later age of onset …
Authors
Selina M Yogeshwar,Sergio Muñiz-Castrillo,Lidia Sabater,Vicente Peris-Sempere,Vamsee Mallajosyula,Guo Luo,Han Yan,Eric Yu,Jing Zhang,Ling Lin,Flavia Fagundes Bueno,Xuhuai Ji,Géraldine Picard,Véronique Rogemond,Anne Laurie Pinto,Anna Heidbreder,Romana Höftberger,Francesc Graus,Josep Dalmau,Joan Santamaria,Alex Iranzo,Bettina Schreiner,Maria Pia Giannoccaro,Rocco Liguori,Takayoshi Shimohata,Akio Kimura,Yoya Ono,Sophie Binks,Sara Mariotto,Alessandro Dinoto,Michael Bonello,Christian J Hartmann,Nicola Tambasco,Pasquale Nigro,Harald Prüss,Andrew McKeon,Mark M Davis,Sarosh R Irani,Jérôme Honnorat,Carles Gaig,Carsten Finke,Emmanuel Mignot
Journal
Brain
Published Date
2024/3/1
Systems-level immunomonitoring in children with solid tumors
Background: Cancer is the leading cause of death from disease in children. Curing cancer requires cytostatic drugs and radiation, as well as systemic immune responses to clear malignant cells. Determinants of such responses in children of different ages and with different tumors are unknown. Novel immunotherapies can potentiate anti-tumor immune responses, but so far, very few children with solid tumors have benefitted and markers of productive anti-tumor immune responses in children are lacking. Methods: 119 children at the Section for Pediatric Oncology, Astrid Lindgren Children’s Hospital, Karolinska University Hospital in Stockholm, Sweden, diagnosed with solid tumors were recruited to Immune Systems Against Cancer in Children (ISAC) cohort from March 2018 to April 2021. Whole blood samples were collected for immune cell composition (Mass cytometry), plasma protein abundances (Olink assays …
Authors
Qi Chen,Binbin Zhao,Ziyang Tan,Gustav Hedberg,Jun Wang,Laura Gonzalez,Constantin Mugabo,Anette Johnsson,Laura Páez,Lucie Rodriguez,Anna James,Yang Chen,Jaromir Mikes,Hugo Barcenilla,Chunlin Wang,Mark M Davis,Lena-Maria Carlson,Niklas Pal,Nikolas Herold,Klas Blomgren,Dirk Repsilber,Tadepally Lakshmikanth,Per Kogner,Linda Ljungblad,Petter Brodin
Journal
Cancer Research
Published Date
2024/3/22
Restrained memory CD8+ T cell responses favors viral persistence and elevated IgG responses in patients with severe Long COVID.
During the COVID-19 pandemic it was widely described that certain individuals infected by SARS-CoV-2 experience persistent disease signs and symptoms, Long COVID, which in some cases is very severe with life changing consequences. To maximize our chances of identifying the underpinnings of this illness, we have focused on 121 of the most severe cases from >1000 patients screened in specialized clinics in Sweden and Belgium. We restricted this study to subjects with objective measures of organ damage or dysfunction, >3 months following a verified, but mild- to-moderate SARS-CoV-2 infection. By performing systems-level immunological testing and comparisons to controls fully convalescent following a similar mild/moderate COVID-19 episode, we identify elevated serological responses to SARS-CoV-2 in severe Long COVID suggestive of chronic antigen stimulation. Persistent viral reservoirs have been proposed in Long COVID and using multiple orthogonal methods for detection of SARS-CoV-2 RNA and protein in plasma we identify a subset of patients with detectable antigens, but with minimal overlap across assays, and no correlation to symptoms or immune measurements. Elevated serologic responses to SARS-CoV-2 on the other hand were inversely correlated with clonally expanded memory CD8+ T cells, indicating that restrained clonal expansion enables viral persistence, chronic antigen exposure and elevated IgG responses, even if antigen-detection in blood is not universally possible.
Authors
Lucie Rodriguez,Ziyang Tan,Lakshmi Kanth Tadepally,Jun Wang,Hugo Barcenilla,Zoe Swank,Fanglei Zuo,Hassan Abolhassani,Ana Jimena Pavlovitch-Bedzyk,Chunlin Wang,Laura Gonzalez,Constantin Habimana Mugabo,Anette Johnsson,Yang Chen,Anna James,Jaromir Mikes,Linn Kleberg,Christopher Sundling,Mikael Bjornson,Malin Nygren-Bonnier,Marcus Stahlberg,MIchael Runold,Sofia Bjorkander,Erik Melen,Isabelle Meyts,Johan Van Weyenbergh,Qiang Pan Hammarstrom,Mark M Davis,David R Walt,Nils Landegren,COVID Human Genetic Effort,Alessandro Aiuti,Giorgio Casari,Jean-Laurent Casanova,MARC JAMOULLE,Judith Bruchfeld,Petter Brodin
Journal
medRxiv
Published Date
2024
Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques
Genetic engineering of allogeneic cell therapeutics that fully prevents rejection by a recipient’s immune system would abolish the requirement for immunosuppressive drugs or encapsulation and support large-scale manufacturing of off-the-shelf cell products. Previously, we generated mouse and human hypoimmune pluripotent (HIP) stem cells by depleting HLA class I and II molecules and overexpressing CD47 (B2M−/−CIITA−/−CD47+). To determine whether this strategy is successful in non-human primates, we engineered rhesus macaque HIP cells and transplanted them intramuscularly into four allogeneic rhesus macaques. The HIP cells survived unrestricted for 16 weeks in fully immunocompetent allogeneic recipients and differentiated into several lineages, whereas allogeneic wild-type cells were vigorously rejected. We also differentiated human HIP cells into endocrinologically active pancreatic islet cells …
Authors
Xiaomeng Hu,Kathy White,Ari G Olroyd,Rowena DeJesus,Antonia A Dominguez,William E Dowdle,Annabelle M Friera,Chi Young,Frank Wells,Elaine Y Chu,Cade Ellis Ito,Harini Krishnapura,Surbhi Jain,Ramya Ankala,Trevor J McGill,August Lin,Kyla Egenberger,Allison Gagnon,J Michael Rukstalis,Nathaniel J Hogrebe,Corie Gattis,Ron Basco,Jeffrey R Millman,Paul Kievit,Mark M Davis,Lewis L Lanier,Andrew J Connolly,Tobias Deuse,Sonja Schrepfer
Journal
Nature biotechnology
Published Date
2024/3
Professor FAQs
What is Mark M. Davis's h-index at Stanford University?
The h-index of Mark M. Davis has been 99 since 2020 and 167 in total.
What are Mark M. Davis's top articles?
The articles with the titles of
Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus
IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
Lineage tracing defines responding CAR T cells in patients with B cell malignancies
Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study
HLA-DQB1* 05 subtypes and not DRB1* 10: 01 mediates risk in anti-IgLON5 disease
Systems-level immunomonitoring in children with solid tumors
Restrained memory CD8+ T cell responses favors viral persistence and elevated IgG responses in patients with severe Long COVID.
Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques
...
are the top articles of Mark M. Davis at Stanford University.
What are Mark M. Davis's research interests?
The research interests of Mark M. Davis are: immunology
What is Mark M. Davis's total number of citations?
Mark M. Davis has 108,842 citations in total.